The diffuse large B-cell lymphoma (DLBCL) market size was USD 4.7 billion in the leading markets (the US, EU4, UK, and Japan) in 2024. The DLBCL market is expected to cross USD 11.5 billion by 2034 in the United States. Factors such as an increase, along with the usage and expansion of approved CAR-Ts and Bi-specifics in earlier lines. The DLBCL drug development clinical trial landscape includes classes such as allogeneic CAR-Ts, monoclonal antibodies, and bispecifics, along with novel mechanisms such as PKC B inhibitor, BTK inhibitor, SYK inhibitor, CD30-directed antibody-drug conjugate, Immunotherapy, and others.
DelveInsight's Diffuse Large B-cell Lymphoma Market Insightsreport includes a comprehensive understanding of current treatment practices, diffuse large B-cell lymphomaemerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].
https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
Diffuse Large B-cell Lymphoma Market Report Summary
— The diffuse large B-cell lymphoma (DLBCL) market size was USD 4.7 billion in the leading Markets (US, EU4, UK, and Japan) in 2024.
— Leading Diffuse large B-cell lymphoma (DLBCL) companies working in the domain such as BMS, Roche (Genentech), Biogen, Nektar Therapeutics, Merck, Allogene Therapeutics, Miltenyi Biomedicine, AstraZeneca, BioVaxys, ImmunoVaccine Technologies, Cellectar Biosciences, Galapagos, Novartis, Lyell, ImmPACT Bio, Pfizer, Kartos Therapeutics, 2seventy bio, Regeneron Pharmaceuticals, BeiGene, Ranok Therapeutics, Constellation Pharmaceuticals, Genmab, IDP Discovery Pharma S.L., Immunitas Therapeutics, Monte Rosa Therapeutics, SymBio Pharmaceuticals, Eagle Pharma, AVM Biotechnology, Autolus Therapeutics, Kymera Therapeutics, Otsuka Pharmaceutical, Caribou Biosciences, Adicet Bio, Gilead Sciences, Xynomic Pharmaceuticals, Amgen, and others are expected to launch their therapies during the forecast period.
— Emerging DLBCL therapies such as Zilovertamab vedotin (Merck), Zamtocabtagene autoleucel (Miltenyi Biomedicine), Cemacabtagene ansegedleucel (Allogene Therapeutics), Rapcabtagene autoleucel (Novartis), Golcadomide (BMS), and others are expected to enter the market by 2034 and are expected to transform the market.
— Label expansion of already approved therapies like EPKINLY/TEPKINLY, COLUMVI, KEYTRUDA, MONJUVI/MINJUVI, POLIVY, YESCARTA, BREYANZI, KYMRIAH, and others are anticipated to increase the DLBCL market size in the coming years, assisted by an increase in the population of DLBCL.
— Approximately 60% of DLBCL patients achieve remission with frontline R-CHOP therapy, while 40% either relapse or remain refractory. Traditionally, these patients undergo salvage chemotherapy with regimens like R-GemOx, R-ICE, or R-DHAP, though none have demonstrated clear superiority.
— YESCARTA (axicabtagene ciloleucel), BREYANZI (lisocabtagene maraleucel), and KYMRIAH (tisagenlecleucel) are three FDA-approved CAR T-cell therapies for relapsed or refractory DLBCL, with no first-line approvals. Gilead/Kite is evaluating YESCARTA in the first-line setting, which could introduce significant competition to already approved first-line therapies.
— EPKINLY (epcoritamab-bysp) and COLUMVI (glofitamab-gxbm), both approved in 2023, offer innovative third-line treatments for LBCL. EPKINLY has shown stronger uptake compared to COLUMVI, benefiting from approvals in the US, Europe, and Japan, whereas COLUMVI is only approved in the US and Europe.
— With no approved first-line CAR T-cell therapy, Cemacabtagene ansegedleucel (Allogene Therapeutics) is an off-the-shelf, allogeneic CD19 CAR T-cell in the Phase II ALPHA3 trial, assessing its role in first-line consolidation for LBCL patients with MRD post-standard treatment. Its market entry could offer a breakthrough option.
Discover more about the diffuse large B-cell lymphoma treatment market @ Diffuse Large B-cell Lymphoma Medication
Key Factors Driving the Growth of Diffuse Large B-cell Lymphoma Market
Increasing DLBCL Incidence and Aging Population
Global DLBCL incidence exceeds 150,000 cases annually, driven by aging populations (9% aged 65+). In the 7MM, incident cases are projected to reach ~87K by 2034.
Launch of Emerging Targeted DLBCL Therapies and Immunotherapies
The introduction of novel treatment options, such as CAR-T therapies (Allogene Therapeutics's Cemacabtagene ansegedleucel, Miltenyi Biomedicine's Zamtocabtagene autoleucel, Galapagos's GLPG5101, Novartis' Rapcabtagene Autoleucel, Lyell/ImmPACT Bio's IMPT-314, and others), monoclonal antibodies (Genmab's GEN3014), and bispecific antibodies (Roche/Biogen's LUNSUMIO, AstraZeneca's AZD0486, and others), is expected to propel the DLBCL treatment market.
Growing Investment in R&D and DLBCL Clinical Trials
More than 30 pharmaceutical diffuse large B-cell lymphoma companies, including Roche (Genentech), Biogen, AstraZeneca, Merck, Allogene Therapeutics, Novartis, Pfizer, 2seventy bio, Regeneron Pharmaceuticals, BeiGene, Bristol-Myers Squibb, Otsuka Pharmaceutical, Gilead Sciences, Amgen, and others, are investing heavily in developing next-generation DLBCL therapies, resulting in a stronger pipeline and more approvals.
Improved DLBCL Diagnostic Capabilities and Early Detection
Improved diagnostic tools, such as PET-CT and next-generation sequencing, have boosted early detection rates in DLBCL by nearly 20%, enabling risk stratification and personalized treatment approaches. Early-stage diagnosis now accounts for approximately 35-40% of identified cases, resulting in significantly improved survival outcomes.
Diffuse Large B-cell Lymphoma Treatment Market Analysis
The diffuse large B-cell lymphoma (DLBCL) treatment landscape is witnessing significant growth, driven by the evolving therapeutic options and advancements in targeted therapies. The R-CHOP regimen, comprising rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, continues to serve as the standard first-line therapy, particularly for newly diagnosed patients. However, patients with high-risk disease profiles are increasingly receiving more intensive or combination strategies, such as R-CHOP with agents like lenalidomide or bortezomib, which is expanding treatment adoption and driving market growth.
For indolent lymphomas, management strategies range from watchful waiting to radiotherapy or chemotherapy, while aggressive lymphomas demand intensive chemotherapy protocols often supplemented with prophylactic measures to prevent central nervous system (CNS) involvement. The emphasis on multidisciplinary care and supportive therapies to mitigate side effects is further enhancing patient outcomes and influencing market uptake.
The relapsed and refractory DLBCL segment is particularly propelling market expansion, fueled by the introduction of innovative CD19-directed CAR-T therapies. FDA-approved therapies such as YESCARTA and BREYANZI, available since 2022, have rapidly become preferred options for early-relapsed, high-risk patients, highlighting a shift toward precision medicine. Similarly, KYMRIAH, approved for adult patients with relapsed or refractory large B-cell lymphoma (including DLBCL, high-grade B-cell lymphoma, and DLBCL transformed from follicular lymphoma), is contributing to market momentum, although it is not indicated for primary CNS lymphoma.
The growing adoption of these CAR-T cell therapies, coupled with expanding indications and continued R&D investment in next-generation immunotherapies, is expected to further accelerate the DLBCL treatment market. As patient access improves and therapeutic outcomes continue to advance, the market is poised for sustained growth, underscoring the transformative impact of targeted and personalized therapies in hematologic oncology.
To know more about FDA-approved drugs for diffuse large B-cell lymphoma, visit @ Diffuse Large B-cell Lymphoma Treatment
Diffuse Large B-cell Lymphoma Competitive Landscape
DelveInsight's analysts conclude that there are approximately 30 companies working. Some of the drugs in the DLBCL pipeline include Zamtocabtagene Autoleucel (MB-CART2019.1) (Miltenyi Biomedicine), AZD0486 (AstraZeneca), Maveropepimut-S (BioVaxys/ImmunoVaccine Technologies), Cemacabtagene ansegedleucel (cema-cel) (Allogene Therapeutics), IMPT-314 (Lyell/ImmPACT Bio), and others.
Miltenyi Biomedicineis advancing a CAR T-cell therapy aimed at treating adult patients with relapsed or refractory diffuse large B-cell lymphoma who have undergone at least one prior line of therapy. Zamtocabtagene autoleucel (Zamto-Cel) is distinctive in its dual targeting of CD19 and CD20 proteins on B cells.
This investigational therapy has been recognized under the European Union's Priority Medicines (PRIME) scheme for its potential. In August 2020, Miltenyi Biomedicine received Orphan Drug Designation (ODD) from the European Commission for MB-CART2019.1 for the treatment of DLBCL. Interim results from the Phase II DALY II USA trial of Zamto-Cel in patients with relapsed or refractory DLBCL were presented by Miltenyi Biomedicine in December 2024.
AZD0486 is an innovative IgG4, fully human CD19 x CD3 bispecific T-cell engager (TCE), designed with low-affinity binding to CD3 to minimize cytokine release while maintaining potent T-cell-mediated cytotoxicity against cancerous B cells. The therapy showed activity and was well tolerated in patients with relapsed or refractory B-cell non-Hodgkin lymphoma, including those with DLBCL.
The anticipated launch of these emerging DLBCL therapies are poised to transform the diffuse large B-cell lymphoma market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the diffuse large B-cell lymphoma market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
Discover more about diffuse large B-cell lymphomadrugsin development @ Diffuse Large B-cell Lymphoma Clinical Trials
Recent Developments in the Diffuse Large B-cell Lymphoma Market
— In June 2025, Genmab announced epcoritamab in combination with rituximab, ifosfamide, carboplatin, and etoposide (R-ICE) demonstrates high response rates in patients with R/R DLBCL eligible for autologous stem cell transplantation.
— In April 2025, the European Commission approved COLUMVI in combination with gemcitabine and oxaliplatin for the treatment of adult patients with relapsed or refractory DLBCL not otherwise specified who are ineligible for autologous stem cell transplant.
— In March 2025,Imugene received FDA Fast Track designation for its allogeneic CAR T-cell therapy, azer-cel (azercabtagene zapreleucel), for treating relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
— In February 2025,the US FDA approved ADCETRIS in combination with lenalidomide and a rituximab product for adult patients with relapsed or refractory large B-cell lymphoma (LBCL), including DLBCL not otherwise specified (NOS), DLBCL arising from indolent lymphoma, or high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy who are ineligible for autologous hematopoietic stem cell transplantation (auto-HSCT) or CAR T-cell therapy.
Diffuse Large B-cell Lymphoma Epidemiology Segmentation
The latest report provides comprehensive insights into the DLBCL patient pool, incident cases, and how the DLBCL patient population is going to increase by 2034. The analysts report that the incident cases are projected to reach ~87K by 2034 in the 7MM. The diffuse large B-cell lymphomaepidemiology section provides insights into the historical and current diffuse large B-cell lymphomapatient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders.
The diffuse large B-cell lymphomamarket reportproffers epidemiological analysis for the study period 2020-2034 in the 7MM, segmented into:
— Total Incident Cases of DLBCL
— Gender-specific Cases of DLBCL
— Age-specific Cases of DLBCL
— Type-specific Cases of DLBCL
— Stage-specific Incident Cases of DLBCL
Scope of the Diffuse Large B-cell LymphomaMarket Report
— DLBCL Therapeutic Assessment: Diffuse Large B-cell Lymphomacurrent marketed and emerging therapies
— Diffuse Large B-cell LymphomaMarket Dynamics:Key Market Forecast Assumptions of Emerging Diffuse Large B-cell LymphomaDrugs and Market Outlook
— Competitive Intelligence Analysis:SWOT analysis, Conjoint analysis, and Market entry strategies
— Unmet Needs, KOL's views, Analyst's views, Diffuse Large B-cell Lymphoma Market Access and Reimbursement
Download the report to understand the diffuse large B-cell lymphoma markettrends @Diffuse Large B-cell Lymphoma Market Report
Table of Contents
Related Reports
Diffuse Large B-cell LymphomaClinical Trial Analysis
Diffuse Large B-cell LymphomaPipeline Insight -2025report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key DLBCL companies, including Miltenyi Biomedicine, Adicet Bio, VelosBio, Novartis Pharmaceuticals, Sanofi, Eisai Co, Schrodinger, Sana Biotechnology, Ranok Therapeutics, Monte Rosa Therapeutic, Otsuka Pharmaceutical, Regeneron Pharmaceuticals, Hoffmann-La Roche, Celgene, Nurix Therapeutics, NovalGen, Nektar Therapeutics, Genentech, CSPC ZhongQi Pharmaceutical Technology, among others.
Non-Hodgkin's Lymphoma Market
Non-Hodgkin's Lymphoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key NHL companies, including AbbVie, Genmab, Novartis, Angiocrine Bioscience, Autolus, Zentera Therapeutics, Jiangsu Hengrui Medicine, among others.
Non-Hodgkin's Lymphoma Pipeline
Non-Hodgkin's Lymphoma Pipeline Insight – 2025report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the keyNHL companies, including Novartis, AstraZeneca, Genentech, BioInvent, Genmab, SystImmune, Nordic Nanovector, Pacylex Pharmaceuticals, Artiva Biotherapeutics, Inc., Chipscreen Biosciences, Ltd., Timmune Biotech Inc., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Gilead Sciences, Acerta Pharma BV, Adagene Inc, Conjupro Biotherapeutics, Inc., Rhizen Pharmaceuticals, Juventas Cell Therapy Ltd., Incyte Corporation, HUYA Bioscience International, SecuraBio, Genor Biopharma Co., Ltd., Kyowa Kirin Co., Ltd., Antengene Therapeutics Limited, Regeneron Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Xynomic Pharmaceuticals, Inc., BioTheryX, Inc., UWELL Biopharma, Kronos Bio, Bio-Thera Solutions, Spectrum Pharmaceuticals, Inc., Aptose Biosciences Inc., Miltenyi Biomedicine GmbH, Precision BioSciences, Inc., Teneobio, Inc., TCR2 Therapeutics, IGM Biosciences, Inc., among others.
Follicular Lymphoma Market
Follicular Lymphoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key follicular lymphomacompanies, including Merck Sharp and Dohme, AstraZeneca, CRISPR Therapeutics, BeiGene, Nektar Therapeutics, NovalGen, Carna Biosciences, Allogene Therapeutics, Xynomic Pharmaceuticals, Bristol-Myers Squibb, Incyte Corporation, among others.
AboutDelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platformPharmDelve.
Contact UsShruti Thakur info@delveinsight.com +14699457679www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
https://c212.net/c/img/favicon.png?sn=IO60105&sd=2025-08-27
View original content:https://www.prnewswire.com/news-releases/diffuse-large-b-cell-lymphoma-market-to-grow-at-a-cagr-of-13-by-2034-in-leading-markets-us-eu4-uk-and-japan–delveinsight-302539884.html
SOURCE DelveInsight Business Research, LLP
https://rt.newswire.ca/rt.gif?NewsItemId=IO60105&Transmission_Id=202508271731PR_NEWS_USPR_____IO60105&DateId=20250827